.
Seroprotection rates and geometric mean titers (GMTs) against hepatitis B after vaccination with Twinrix on a 0-, 1-, and 6-month schedule. The above statements might lead to the misconception that interference with the hepatitis B response may occur after administration of any combined hepatitis A and B vaccine. However, there are sufficient published data to demonstrate that SmithKline Beecham Biologicals' combined hepatitis A and B vaccine, Twinrix, administered on a 0-, 1-, 6-month schedule, induces a strong immune response to both vaccine components. Pooled data from 6 pivotal clinical trials [2] carried out in young adults demonstrated high seroprotection rates and geometric mean titers (GMTs) against hepatitis B after vaccination with Twinrix (on a 0-, 1-, and 6-month schedule), as is shown in table 1.
Additionally, in a US study conducted in adults (more than half were 140 years old), the immunogenicity of Twinrix (administered as a 3-dose series) was compared with separate injections of the corresponding monovalent products. A better immune response to the hepatitis B component was demonstrated in the combined vaccine than in the monovalent vaccine [3] . After the third dose, 95.1% of subjects receiving Twinrix and 92.2% of subjects receiving Engerix-B had protective titers. GMTs were 2099 mIU/mL and 1871 mIU/mL for Twinrix and Engerix-B, respectively.
In conclusion, although Frey et al. [1] did show interference with the hepatitis B response after administration of the combination hepatitis A and B vaccine developed by Merck & Co., SmithKline Beecham Biologicals' combination hepatitis A and B vaccine, Twinrix, shows no evidence of interference with either component.
Betsy Abraham and Dennis Parenti
SmithKline Beecham, Collegeville, Pennsylvania
Reply
To the Editor-The following clarification is in response to the letter by Abraham and Parenti [1] , from SmithKline Beecham (Collegeville, PA) in regard to our December 1999 article in the Journal [2] .
In the last paragraph of the introduction, Twinrix (SmithKline Beecham Biologicals, Rixensart, Belgium) was mentioned as a positive example, indicating that hepatitis A and hepatitis B vaccines could be given in one injection. It was not the authors' intention to make the reader think that this study was undertaken using Twinrix. This would have been clarified in the Materials and Methods section, under Vaccines, but, unfortunately, SmithKline Beecham was listed after we mentioned the RECOMBIVAX HB/H-B-VaxII vaccine product. This in-formation was published in an erratum in the February issue of the Journal [2] . This is an obvious error, because the study, funded by Merck & Co., used the Merck & Co. product RE-COMBIVAX HB/H-B-VaxII. The Discussion section discussed only the use of RECOMBIVAX HB/H-B-VaxII as a 2-dose regimen. It was not our intent to suggest that the Twinrix product did not stimulate a good immunologic response. We regret any confusion that this may have caused for the reader, and we certainly regret the concerns that it has caused for SmithKline Beecham and Merck & Co.
